Zaotong International Group

Zaotong International Group is a prominent private investment holding company based in Hong Kong that serves as the controlling entity for Lee's Pharmaceutical Holdings Limited and holds significant interests in Zhaoke Ophthalmology. The group operates as a fully integrated biopharmaceutical organization with extensive capabilities in research, development, manufacturing, and commercialization of therapeutic products across Greater China. Its portfolio encompasses a wide range of therapeutic areas, including cardiovascular disease, oncology, ophthalmology, dermatology, and women's health. With key manufacturing and R&D hubs in Hefei and Guangzhou, the group leverages a combination of internal innovation and strategic international licensing partnerships to maintain a robust pipeline of over 40 projects. Notable late-stage assets include socazolimab, an anti-PD-L1 antibody, and anfibatide, a first-in-class anti-thrombotic peptide.